Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price was up 6.9% on Friday . The stock traded as high as C$1.08 and last traded at C$1.08. Approximately 159,486 shares traded hands during trading, an increase of 255% from the average daily volume of 44,869 shares. The stock had previously closed at C$1.01.
Medicenna Therapeutics Trading Up 17.8%
The firm has a market capitalization of C$89.03 million, a price-to-earnings ratio of -3.28 and a beta of 1.21. The company has a fifty day moving average price of C$0.88 and a two-hundred day moving average price of C$1.02. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88.
About Medicenna Therapeutics
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Best Stocks Under $10.00
- Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
- 3 Healthcare Dividend Stocks to Buy
- Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
- How to Read Stock Charts for Beginners
- Now Is a Great Time to Buy Cheniere Energy: New High Expected
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
